PW Medtech Group (1358) H1 2024 earnings summary

Executive summary

• Revenue for the first half of 2024 reached RMB338.4 million, up 6.1% year-over-year, driven by growth in the Blood Purification Business.

• Gross profit increased 6.1% to RMB187.6 million, with a stable gross margin of 55.4%.

• Profit attributable to owners was RMB70.2 million, down 1.1% year-over-year, mainly due to higher tax expenses and lower other gains.

• Adjusted profit attributable to owners increased 3.4% to RMB73.4 million, excluding share-based compensation and spin-off costs.

• Interim dividend declared at HK4.5 cents per share, down from HK4.9 cents last year.

Financial highlights

• Blood Purification Business revenue rose 10.0% to RMB205.8 million, accounting for 60.8% of total revenue.

• Infusion Set Business revenue was RMB132.6 million, up 0.6% year-over-year.

• Operating profit decreased 4.1% to RMB84.5 million; net finance income grew 37.2% to RMB27.8 million.

• R&D expenses decreased 10.3% to RMB20.6 million; selling and marketing expenses rose 1.8% to RMB39.9 million.

• Net other gains dropped 46.1% due to absence of one-off government subsidies.

Outlook and guidance

• The company expects continued growth in medical device demand due to public health awareness and an aging population.

• Centralized procurement is expected to drive industry innovation and cost efficiency, benefiting competitive firms.

• Focus remains on innovation, R&D, and expanding product portfolio across three business segments.

• The Regenerative Medical Biomaterials segment is seen as a high-growth area for future investment.